An Exploratory Clinical Study to Evaluate the Specificity of Magnetocardiogram in Atrial Fibrillation and the Prediction of Recurrence

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05887453
Collaborator
(none)
450
1
8.3
53.9

Study Details

Study Description

Brief Summary

This is a prospective, observational clinical study with150 patients of persistent AF (trial group 1), 150 patients of paroxysmal AF (trial group 2), and 150 healthy subjects (control group). The trial is divided into two parts. The aim of first part is to evaluate the sensitivity and specificity of magnetocardiography on diagnosing persistent AF, and the second part is to evaluate the independent predictors of magnetocardiography on predicting recurrence of paroxysmal AF. The patients who had been diagnosed with AF in OPD or IPD will be included. After signing the informed consent letter, medical history of all subjects will be collected, including magnetic cardiogram, 12-lead electrocardiogram, holter electrocardiogram, cardiac ultrasound and blood tests. Patients with paroxysmal AF will be followed up for 3 months, and the recurrence of AF is the observation end point.

Condition or Disease Intervention/Treatment Phase
  • Device: Magnetocardiography

Study Design

Study Type:
Observational
Anticipated Enrollment :
450 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
An Exploratory Clinical Study to Evaluate the Specificity of Magnetocardiogram in Atrial Fibrillation and the Prediction of Recurrence
Actual Study Start Date :
Mar 22, 2023
Anticipated Primary Completion Date :
Aug 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Group 1: Persistent AF

Device: Magnetocardiography
Magnetocardiography is a device used to exam the dynamic magnetic map of the heart for the diagnosis of some heart diseases

Group 2 : Paroxysmal AF

Device: Magnetocardiography
Magnetocardiography is a device used to exam the dynamic magnetic map of the heart for the diagnosis of some heart diseases

Healthy controls

Device: Magnetocardiography
Magnetocardiography is a device used to exam the dynamic magnetic map of the heart for the diagnosis of some heart diseases

Outcome Measures

Primary Outcome Measures

  1. sensitivity and specificity [24 hours]

    The sensitivity and specificity of magnetocardiography in the diagnosis of persistent AF

  2. Independent predictors of recurrence of paroxysmal atrial fibrillation [3 months]

    A statistical model is used to obtain the magnetocardiographic parameters that could predict the recurrence of paroxysmal atrial fibrillation.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes

Group: Group 1 (Persistent AF)

Inclusion criteria:

  • Persistent AF is recorded by ECG before the examination of the magnetocardiogram;

  • Detailed clinical records, including medical history, cardiovascular risk factors, blood tests, and antiarrhythmic drug therapy;

  • It is recommended that antiarrhythmic drugs be discontinued at least 5 days before the examination and continue if atrial fibrillation occurs or the symptoms of atrial fibrillation are obvious;

Exclusion criteria:
  • Severe valvular heart disease, structural heart disease, heart function classification ≥ New York Heart Association functional class II, history of ischemic heart disease, left ventricular ejection fraction < 50%, hyperthyroidism, primary pulmonary hypertension, and respiratory disease;

  • Patients after radiofrequency ablation;

  • The implanted devices in the body effect the magnetic signal during the detection process, such as prosthetic limbs, heart stents or valves contain metal material.

  • Unable to maintain the supine position during the examination.

Group: Group 2 (Paroxysmal AF)

Inclusion criteria:
  • Persistent AF is recorded by ECG before the examination of the magnetocardiogram;

  • Detailed clinical records, including medical history, cardiovascular risk factors, blood tests, and antiarrhythmic drug therapy;

  • It is recommended that antiarrhythmic drugs be discontinued at least 5 days before the examination and continue if atrial fibrillation occurs or the symptoms of atrial fibrillation are obvious;

Exclusion criteria:
  • Severe valvular heart disease, structural heart disease, heart function classification ≥ New York Heart Association functional class II, history of ischemic heart disease, left ventricular ejection fraction < 50%, hyperthyroidism, primary pulmonary hypertension, and respiratory disease;

  • Patients after radiofrequency ablation;

  • The implanted devices in the body effect the magnetic signal during the detection process, such as prosthetic limbs, heart stents or valves contain metal material.

  • Unable to maintain the supine position during the examination.

Group: Control group

Inclusion criteria:
  • No history of AFor other arrhythmias;

  • Detailed clinical records, including medical history and cardiovascular risk factors;

Exclusion criteria:
  • severe valvular heart disease, structural heart disease,heart function classification ≥ New York Heart Association functional class II, history of ischemic heart disease, left ventricular ejection fraction < 50%, hyperthyroidism, primary pulmonary hypertension, and respiratory disease;

  • The implanted devices in the body effect the magnetic signal during the detection process, such as prosthetic limbs, heart stents or valves contain metal material.

  • Unable to maintain the supine position during the examination.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China 310009

Sponsors and Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

Investigators

  • Principal Investigator: Jian'an Wang, Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Second Affiliated Hospital, School of Medicine, Zhejiang University
ClinicalTrials.gov Identifier:
NCT05887453
Other Study ID Numbers:
  • JWang
First Posted:
Jun 2, 2023
Last Update Posted:
Jun 2, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 2, 2023